Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182685 | 0.78 | HSD17B10 (0.31) | HSD17B10 | |
| SCHEMBL18552566 | 0.72 | — | — | |
| SCHEMBL440668 | 0.70 | HSD17B10 (0.34) | HSD17B10 | |
| SCHEMBL180596 | 0.69 | — | — | |
| SCHEMBL141255 | 0.69 | HSD17B10 (0.44) | HSD17B10 | |
| SCHEMBL16808034 | 0.69 | — | — | |
| SCHEMBL5104157 | 0.68 | — | — | |
| SCHEMBL4370824 | 0.67 | ADRA2B (0.38) | — | |
| SCHEMBL24583250 | 0.67 | — | — | |
| SCHEMBL22761495 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | claimed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-119110804-A | KRAS modulators and uses thereof | 光达治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | HSD17B10 2280/4885 |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | HSD17B10 2285/4885 |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | HSD17B10 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.